Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value

Core Viewpoint - Neuphoria Therapeutics Inc. is exploring strategic alternatives to enhance its pipeline and maximize stockholder value, including potential mergers, acquisitions, and partnerships [2][3][5]. Strategic Alternatives - The company has engaged H.C. Wainwright & Co. as its exclusive financial advisor to assist in evaluating strategic options [3]. - There is no defined timeline for this exploration, and the company does not guarantee that any strategic alternatives will be finalized [3]. Unsolicited Offer - On November 10, 2025, Neuphoria received an unsolicited non-binding indication of interest from Lynx1 Master Fund LP to acquire all outstanding shares for $5.20 per share in cash [4]. - Lynx1 Master Fund LP also intends to nominate individuals for election to Neuphoria's Board of Directors at the upcoming Annual Meeting [4]. Board of Directors' Response - Neuphoria's Board is committed to acting in the best interests of all stockholders and will evaluate the unsolicited offer in conjunction with its strategic alternatives review [5]. - The Board will present its recommendations regarding director nominees in the proxy statement for the 2025 Annual Meeting [6]. Annual Meeting Details - The 2025 Annual Meeting is scheduled for December 12, 2025, with a record date of October 15, 2025 [6]. - Stockholders are not required to take any action at this time [7]. Company Overview - Neuphoria is a clinical-stage biotechnology company focused on developing treatments for neuropsychiatric disorders [9]. - The company previously advanced its lead drug candidate, BNC210, for social anxiety disorder and PTSD but halted its development following unsuccessful clinical trial results [9]. - Neuphoria has a partnership with Merck & Co. for two drugs in early-stage clinical trials targeting cognitive deficits in Alzheimer's disease [9].